Godavari Biorefineries Ltd
Incorporated in 1939, Godavari Biorefineries Ltd is a manufacturer of Bio-based Chemicals and Ethanol[1]
- Market Cap ₹ 1,254 Cr.
- Current Price ₹ 245
- High / Low ₹ 388 / 145
- Stock P/E 28.8
- Book Value ₹ 139
- Dividend Yield 0.00 %
- ROCE 5.50 %
- ROE -0.41 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 34.6 to 25.5 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.05% over past five years.
- Company has a low return on equity of 1.28% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 1,449 | 1,526 | 1,691 | 2,000 | 1,675 | 1,853 | 1,967 | |
| 1,347 | 1,372 | 1,560 | 1,861 | 1,544 | 1,753 | 1,824 | |
| Operating Profit | 102 | 155 | 131 | 139 | 132 | 100 | 143 |
| OPM % | 7% | 10% | 8% | 7% | 8% | 5% | 7% |
| 13 | 7 | 6 | 6 | 14 | 16 | -10 | |
| Interest | 68 | 72 | 60 | 73 | 76 | 72 | 59 |
| Depreciation | 45 | 47 | 48 | 50 | 60 | 50 | 52 |
| Profit before tax | 2 | 43 | 29 | 23 | 10 | -5 | 21 |
| Tax % | -53% | 43% | 44% | 49% | -2% | -51% | |
| 3 | 25 | 16 | 12 | 11 | -3 | 17 | |
| EPS in Rs | 0.60 | 5.86 | 3.89 | 2.86 | 2.52 | -0.52 | 3.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -48% |
| 3 Years: | % |
| TTM: | 4060% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 42 | 42 | 42 | 42 | 42 | 51 | 51 |
| Reserves | 392 | 416 | 432 | 442 | 452 | 721 | 661 |
| 584 | 564 | 634 | 739 | 655 | 488 | 490 | |
| 419 | 417 | 625 | 517 | 838 | 683 | 244 | |
| Total Liabilities | 1,437 | 1,440 | 1,734 | 1,740 | 1,987 | 1,944 | 1,446 |
| 733 | 706 | 666 | 866 | 849 | 862 | 860 | |
| CWIP | 17 | 9 | 50 | 17 | 29 | 38 | 82 |
| Investments | 14 | 14 | 14 | 16 | 16 | 16 | 16 |
| 673 | 711 | 1,004 | 842 | 1,093 | 1,028 | 488 | |
| Total Assets | 1,437 | 1,440 | 1,734 | 1,740 | 1,987 | 1,944 | 1,446 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 240 | 129 | 40 | 185 | 196 | -1 | |
| -28 | -8 | -47 | -217 | -45 | -61 | |
| -211 | -120 | 7 | 31 | -151 | 63 | |
| Net Cash Flow | 0 | 0 | 1 | -1 | 1 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 30 | 39 | 38 | 39 | 40 | 26 |
| Inventory Days | 131 | 147 | 250 | 194 | ||
| Days Payable | 124 | 133 | 197 | 141 | ||
| Cash Conversion Cycle | 37 | 53 | 38 | 39 | 92 | 79 |
| Working Capital Days | -69 | 0 | 4 | 3 | -17 | 18 |
| ROCE % | 11% | 8% | 8% | 7% | 6% |
Documents
Announcements
-
Announcement Under Regulation 30 - Grant Of Patent
5 Dec - US patent granted Nov 4, 2025 for anti-cancer compounds targeting cancer stem cells.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
20 Nov - Transcript of Earning Call held on 14th November, 2025
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Nov - Newspaper clip regarding the special window for re-lodgement of transfer request of physical shares
-
Announcement under Regulation 30 (LODR)-Acquisition
19 Nov - Sathgen Therapeutics LLC incorporated in USA on 17 Nov 2025; US$350,000 capital; 100% step-down subsidiary.
-
General Update - Sustainability Report
17 Nov - Sustainability Report FY2024-25 uploaded November 17, 2025; ESG performance and initiatives link provided.
Annual reports
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
Business Overview:[1][2]
a) GBL is a part of the Somaiya group which holds 63.31% equity stake in the company through entities.
b) It has an Integrated Bio-refinery across value chain viz. Sugar, Branded Sugar, Ethanol, Bio Based Chemicals & Power
c) It has India’s first bio-based Ethyl Vinyl Ether (EVE) manufacturing facility in India
d) Company is the largest Manufacturer of MPO in India in terms of installed capacity
e) It is one of only 2 Manufacturers of natural 1,3 Butylene Glycol (BG) globally
f) The company has an in-house retail brand Jivana for sale of sugar, turmeric, and salt in Rajasthan Maharashtra, Karnataka, and Gujarat.